/

Empresas

Te

No verificado

Tensive

Sobre qué escribimos

Anuncios brevesFinanzasMedicina Salud Bienestar

9 Comunicados de prensa

Ver todos los comunicados de prensa

02/09/2026

Medicina Salud Bienestar

Anuncios breves

Finanzas

Tensive to receive €20 million from EIB to commercialize bioresorbable breast implant

Fuente

Editor

1.00

0

27/07/2026

Medicina Salud Bienestar

Anuncios breves

Tensive reports pivotal 12-month clinical trial data confirming REGENERA™ delivers natural breast reconstruction after lumpectomy

Fuente

Editor

1.00

0

07/07/2026

Medicina Salud Bienestar

Anuncios breves

Tensive appoints Peter Crosby Chairman as its bioresorbable breast reconstruction scaffold approaches regulatory approval

Fuente

Editor

1.00

0

14/04/2026

Medicina Salud Bienestar

Anuncios breves

Tensive publishes positive interim pivotal clinical data showing REGENERA™ supports natural breast reconstruction in Updates in Surgery

Fuente

Editor

1.00

0

07/01/2026

Medicina Salud Bienestar

Tensive reports positive pivotal trial top-line results showing REGENERA™ bioresorbable device may transform breast reconstruction

Fuente

Editor

1.00

0

05/09/2025

Medicina Salud Bienestar

Tensive annuncia aggiornamenti clinici positivi che evidenziano il potenziale del dispositivo REGENERA™ / SOFTAG™ per la ricostruzione del seno post-lumpectomia

Fuente

Editor

1.00

0

05/09/2025

Medicina Salud Bienestar

Tensive provides positive clinical updates highlighting potential of REGENERA™ / SOFTAG™ device to transform post-cancer breast reconstruction

Fuente

Editor

1.00

0

04/08/2025

Medicina Salud Bienestar

Tensive nomina Bill Hunter, esperto riconosciuto nei dispositivi medici, Presidente del CdA, mentre il suo scaffold bioassorbibile per la ricostruzione del seno post-tumore si avvicina alla commercializzazione

Fuente

Editor

1.00

0

04/08/2025

Medicina Salud Bienestar

Tensive appoints medical device veteran Bill Hunter Chairman as its bioresorbable scaffold for breast reconstruction after cancer approaches market

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0